Efficacy of doxorubicin and lipiodol therapy by trans-arterial chemoembolization in hepatocellular carcinoma Egyptian patients and relation to genetic polymorphisms.

IF 2.9 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2024-10-01 Epub Date: 2024-08-21 DOI:10.1080/14737140.2024.2391364

Rehab H Werida, Omnia A Abd El Baset, Safaa Askar, Marwa El-Mohamdy, Gamal A Omran, Radwa Samir Hagag

{"title":"Efficacy of doxorubicin and lipiodol therapy by trans-arterial chemoembolization in hepatocellular carcinoma Egyptian patients and relation to genetic polymorphisms.","authors":"Rehab H Werida, Omnia A Abd El Baset, Safaa Askar, Marwa El-Mohamdy, Gamal A Omran, Radwa Samir Hagag","doi":"10.1080/14737140.2024.2391364","DOIUrl":null,"url":null,"abstract":"Background: Genetic polymorphisms play a crucial role in predicting treatment efficacy in patients with hepatocellular carcinoma (HCC). This study aims to evaluate the response to Transarterial Chemoembolization (TACE) in relation to the genetic polymorphisms of interleukin 28B (IL28B) and angiopoietin-2 (ANGPT2) in HCC patients.Research design and methods: Prospective cohort study conducted on 104 eligible HCC Egyptian patients who underwent TACE using doxorubicin and lipiodol. Genotyping of the IL28B and ANGPT2 genes was performed with laboratory data analysis.Results: At baseline IL28B rs12979860 genotypes C/T, C/C and T/T appeared in 43.9%, 34.6% and 21.5% while ANGPT2 rs55633437 genotypes C/C, C/A and A/A found in 71.03%, 28.04% and 0.93% of patients respectively. After one month of therapy, 51.4% of patients achieved a complete response. There was a significant difference in relation to IL28B rs12979860 genotypes (p = 0.017) whereas ANGPT2 rs55633437 genotypes (p = 0.432) showed no significant difference in patient response after one month of TACE.Conclusion: This study demonstrates the effectiveness of TACE in Egyptian HCC patients, as evidenced by low recurrence rates. Furthermore, the IL28B rs12979860 (C/T) gene may be associated with the efficacy and prognosis of TACE treatment in HCC Egyptian patients.Trial registration: The trial is registered at ClinicalTrials.gov (CT.gov identifier: NCT05291338).","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1009-1020"},"PeriodicalIF":2.9000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2024.2391364","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/21 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Genetic polymorphisms play a crucial role in predicting treatment efficacy in patients with hepatocellular carcinoma (HCC). This study aims to evaluate the response to Transarterial Chemoembolization (TACE) in relation to the genetic polymorphisms of interleukin 28B (IL28B) and angiopoietin-2 (ANGPT2) in HCC patients.

Research design and methods: Prospective cohort study conducted on 104 eligible HCC Egyptian patients who underwent TACE using doxorubicin and lipiodol. Genotyping of the IL28B and ANGPT2 genes was performed with laboratory data analysis.

Results: At baseline IL28B rs12979860 genotypes C/T, C/C and T/T appeared in 43.9%, 34.6% and 21.5% while ANGPT2 rs55633437 genotypes C/C, C/A and A/A found in 71.03%, 28.04% and 0.93% of patients respectively. After one month of therapy, 51.4% of patients achieved a complete response. There was a significant difference in relation to IL28B rs12979860 genotypes (p = 0.017) whereas ANGPT2 rs55633437 genotypes (p = 0.432) showed no significant difference in patient response after one month of TACE.

Conclusion: This study demonstrates the effectiveness of TACE in Egyptian HCC patients, as evidenced by low recurrence rates. Furthermore, the IL28B rs12979860 (C/T) gene may be associated with the efficacy and prognosis of TACE treatment in HCC Egyptian patients.

Trial registration: The trial is registered at ClinicalTrials.gov (CT.gov identifier: NCT05291338).

查看原文本刊更多论文

埃及肝细胞癌患者经动脉化疗栓塞治疗多柔比星和脂碘的疗效及与基因多态性的关系。

背景：基因多态性在预测肝细胞癌（HCC）患者的治疗效果方面起着至关重要的作用。本研究旨在评估经动脉化疗栓塞术（TACE）对 HCC 患者的反应与白细胞介素 28B （IL28B）和血管生成素-2（ANGPT2）基因多态性的关系：前瞻性队列研究：对 104 名符合条件的 HCC 埃及患者进行了前瞻性队列研究，这些患者接受了使用多柔比星和脂肪碘的 TACE。通过实验室数据分析对 IL28B 和 ANGPT2 基因进行基因分型：基线IL28B rs12979860基因型为C/T、C/C和T/T的患者分别占43.9%、34.6%和21.5%，而ANGPT2 rs55633437基因型为C/C、C/A和A/A的患者分别占71.03%、28.04%和0.93%。治疗一个月后，51.4% 的患者获得了完全应答。IL28B rs12979860 基因型（p = 0.017）与 TACE 治疗一个月后患者的反应有显著差异，而 ANGPT2 rs55633437 基因型（p = 0.432）与 TACE 治疗一个月后患者的反应无显著差异。结论：本研究证明了 TACE 对埃及 HCC 患者的有效性，复发率低就是证明。此外，IL28B rs12979860 (C/T) 基因可能与埃及 HCC 患者 TACE 治疗的疗效和预后有关：该试验已在 ClinicalTrials.gov 注册（CT.gov 识别码：NCT05291338）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.